Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations-论文-万方医学网

首页> > Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

导出原文传递

翻译打印收藏纠错

第一作者： Wenyuan,Xiong

作者： Wenyuan,Xiong ^[1] ; Sofia Friberg,Hietala ^[2] ; Joakim,Nyberg ^[3] ; Orestis,Papasouliotis ^[4] ; Andreas,Johne ; Karin,Berghoff ; Kosalaram,Goteti ; Jennifer,Dong ; Pascal,Girard ; Karthik,Venkatakrishnan ; Rainer,Strotmann

作者单位： Merck Institute of Pharmacometrics ^[1] Pharmetheus AB ^[2] Merck Healthcare KGaA ^[3] EMD Serono Research and Development Institute Inc. ^[4]

关键词 Tyrosine kinase inhibitor Dose selection Targeted therapies NSCLC METex14 skipping alteration

发布时间 2022-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

相似文献

同项目论文

相关期刊

检索历史 清除

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

相似文献

同项目论文

相关期刊

检索历史清除